Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 287

Sort by

Sort Order Select

Journal Articles

Novel Microfluidic and AI-Based Approach for Personalized Drug Selection in Chronic Myeloid Leukemia (CML) Patients

Hwisu Jeon, Yukyung Park, Eujin Um, Hongtae Kim, Chang-Yeol Jung, Dong-Wook Kim, Taesung Kim

Blood (2024) 144 (Supplement 1): 7482.

https://doi.org/10.1182/blood-2024-199886

Published: 2024

Journal Articles

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Sewon Lee, Yeung-Chul Mun, Hongtae Kim, Sung-Ho Park, Semin Lee, Seunghoon Kim, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Yoonsung Lee, Dong-Wook Kim

Blood (2024) 144 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2024-199242

Published: 2024

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, Sung-Hyun Kim, Young Rok Do, Kyung-Mi Ki, Soo Hyun Kim, Min-Sik Song, Seung-Shick Shin, Dong-Wook Kim

Blood (2024) 144 (Supplement 1): 6596.

https://doi.org/10.1182/blood-2024-206252

Published: 2024

Journal Articles

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Elias Jabbour, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Dong-Wook Kim, Hagop M. Kantarjian, Leanne Holes, Emil T. Kuriakose, Michael J. Mauro

Blood (2024) 144 (Supplement 1): 6594.

https://doi.org/10.1182/blood-2024-204153

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

Ye Seul Lim, Na-Rae Jeong, Sun-Mi Yoo, Han Wool KIM, Song Hee Lee, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 5012.

https://doi.org/10.1182/blood-2023-180442

Published: 2023

Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes

Blood (2023) 142 (Supplement 1): 866.

https://doi.org/10.1182/blood-2023-182100

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Novel Orally Available Degrader to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Na-Rae Jeong, Ye Seul Lim, Sun-Mi Yoo, Han Wool KIM, So Hyuk Kim, Ae-Ran Choi, Dong-Wook Kim, Song Hee Lee

Blood (2023) 142 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2023-185778

Published: 2023

Journal Articles

Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia

Sewon Lee, Hongtae Kim, Semin Lee, Seunghoon Kim, Sung-Ho Park, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 1806.

https://doi.org/10.1182/blood-2023-178408

Published: 2023

Journal Articles

KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy

Sung-Min Ahn, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 6352.

https://doi.org/10.1182/blood-2023-190891

Published: 2023

Journal Articles

Highly Sensitive Chip-Based Digital PCR Platform for Quantitative Detection of BCR::ABL1 Transcripts throughout CML Treatment

Hyun-Woo Song, Sung-Hyun Kim, Young Rok Do, Kyung-Mi Ki, Soo Hyun Kim, Min-Sik Song, Seung-Shick Shin, Dong-Wook Kim

Blood (2023) 142 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2023-185162

Published: 2023

Journal Articles

Chip-Based Digital PCR Platform, Lab on an Array, the Newly Developed Highly Accurate and Sensitive Method for the Detection of BCR-ABL1 Transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, Kyung-Mi Ki, Soo Hyun Kim, Sung-Hyun Kim, Min-Sik Song, Do Young Lee, Seung-Shick Shin, Dong-Wook Kim

Blood (2022) 140 (Supplement 1): 3904–3905.

https://doi.org/10.1182/blood-2022-168020

Published: 2022

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Blood (2022) 140 (Supplement 1): 1498–1500.

https://doi.org/10.1182/blood-2022-159993

Published: 2022

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 195–197.

https://doi.org/10.1182/blood-2022-167177

Published: 2022

Journal Articles

Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML

Gi-June Min, Byung-Sik Cho, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Kim Hee-Je

Blood (2022) 139 (11): 1646–1658.

https://doi.org/10.1182/blood.2021013671

Published: 2022

Includes: Supplemental data

NARROW

Novel Microfluidic and AI-Based Approach for Personalized Drug Selection in Chronic Myeloid Leukemia (CML) Patients

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Novel Orally Available Degrader to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia

KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy

Highly Sensitive Chip-Based Digital PCR Platform for Quantitative Detection of BCR::ABL1 Transcripts throughout CML Treatment

Chip-Based Digital PCR Platform, Lab on an Array, the Newly Developed Highly Accurate and Sensitive Method for the Detection of BCR-ABL1 Transcripts in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only